Activities of Pseudomonas aeruginosa effectors secreted by the Type III secretion system in vitro and during infection.
Pseudomonas aeruginosa utilizes a number of distinct pathways to secrete proteins that play various roles during infection. These include the type II secretion system, which is responsible for the secretion of the majority of exoproducts into the surrounding environment, including toxins and degradative enzymes. In contrast, the type III secretion system mediates the delivery of protein effectors directly into the cytoplasm of the host cell. Using tissue culture assays and a mouse acute-pneumonia model, we have determined the contribution of each of the type III effectors during infection. In strain PAK, ExoS is the major cytotoxin required for colonization and dissemination during infection. ExoT confers protection of tissue culture cells from type III-dependent lysis, while ExoY seemed to have little effect on cytotoxicity. ExoU is over 100-fold more cytotoxic than ExoS. The cytotoxicity of type II secretion was determined following deletion of the genes for the more toxic type III secretion system. The participation of these secretion systems during lifelong colonization of cystic fibrosis (CF) patients is unclear. By comparing clonal strains from the same patient isolated at the initial onset of P. aeruginosa infection and more than a decade later, after chronic colonization has been established, we show that initial strains are more cytotoxic than chronic strains that have evolved to reduce type III secretion. Constitutive expression of genes for the type III secretion system restored ExoS secretion but did not always reestablish cytotoxicity, suggesting that CF strains accumulate a number of mutations to reduce bacterial toxicity to the host.
Lee
Vincent T
VT
Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115, USA.
Smith
Roger S
RS
Tümmler
Burkhard
B
Lory
Stephen
S
D036002:ADP Ribose Transferases / Q000235:genetics / Q000378:metabolism / Q000633:toxicity; D000208:Acute Disease; D000818:Animals; D001426:Bacterial Proteins / Q000235:genetics / Q000378:metabolism* / Q000633:toxicity*; D001427:Bacterial Toxins / Q000235:genetics / Q000633:toxicity; D016466:CHO Cells; D002908:Chronic Disease; D006224:Cricetinae; D003550:Cystic Fibrosis / Q000382:microbiology / Q000503:physiopathology*; D020690:GTPase-Activating Proteins; D005964:Glucosyltransferases / Q000235:genetics / Q000378:metabolism / Q000633:toxicity; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D009154:Mutation; D018410:Pneumonia, Bacterial / Q000382:microbiology* / Q000503:physiopathology; D011552:Pseudomonas Infections / Q000382:microbiology* / Q000503:physiopathology; D011550:Pseudomonas aeruginosa / Q000235:genetics / Q000378:metabolism / Q000472:pathogenicity*
D001426:Bacterial Proteins; D001427:Bacterial Toxins; C477521:ExoT protein, Pseudomonas aeruginosa; D020690:GTPase-Activating Proteins; C111749:pseudomonas exoprotein A protein, Pseudomonas aeruginosa; C111504:ExoY protein, bacteria; D005964:Glucosyltransferases; D036002:ADP Ribose Transferases; C444820:exoenzyme S
J Biol Chem. 1999 Dec 17;274(51):36369-72
10593930
Antibiot Chemother (1971). 1989;42:130-53
2512834
Infect Immun. 2000 Oct;68(10):6066-8
10992524
Infect Immun. 2001 Jan;69(1):538-42
11119548
Infect Immun. 2001 Feb;69(2):1185-8
11160019
Burns. 2001 Mar;27(2):129-30
11226648
Mol Microbiol. 2001 Apr;40(1):76-85
11298277
J Infect Dis. 2001 Jun 15;183(12):1767-74
11372029
EMBO J. 2001 Oct 1;20(19):5373-82
11574469
Microbiology. 2001 Oct;147(Pt 10):2659-69
11577145
J Infect Dis. 2002 Jan 15;185(2):269-70
11807706
Biochem Biophys Res Commun. 2002 Feb 15;291(1):91-100
11829467
Infect Immun. 2002 Apr;70(4):2198-205
11895987
Biochem J. 2002 Nov 1;367(Pt 3):617-28
12132999
J Bacteriol. 2003 Feb;185(3):1071-81
12533483
Dev Cell. 2003 Feb;4(2):253-63
12586068
J Bacteriol. 2003 Apr;185(7):2066-79
12644476
Invest Ophthalmol Vis Sci. 2003 Sep;44(9):3892-8
12939306
J Biol Chem. 2003 Oct 17;278(42):41326-32
12915403
Infect Immun. 2004 Mar;72(3):1677-84
14977975
J Bacteriol. 2004 Jun;186(12):3837-47
15175297
J Infect Dis. 1966 Feb;116(1):112-6
4956054
Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):47-51
1309616
Mol Microbiol. 1992 May;6(9):1121-31
1588814
Science. 1993 May 21;260(5111):1127-30
8493556
Am J Physiol. 1994 Nov;267(5 Pt 1):L551-6
7977765
J Infect Dis. 1994 Dec;170(6):1616-21
7996008
Biochemistry. 1996 Feb 27;35(8):2754-8
8611582
Infect Immun. 1996 Jun;64(6):2288-94
8675339
Microbiol Rev. 1996 Sep;60(3):539-74
8840786
Mol Microbiol. 1996 Dec;22(5):991-1003
8971719
Gene. 1997 Feb 20;186(1):29-35
9047341
Mol Microbiol. 1997 Aug;25(3):547-57
9302017
Infect Immun. 1997 Oct;65(10):4061-7
9317008
Behring Inst Mitt. 1997 Feb;(98):249-55
9382747
Mol Microbiol. 1998 Feb;27(4):807-18
9515706
Infect Immun. 1998 Jun;66(6):2521-8
9596711
Infect Immun. 1998 Jul;66(7):3242-9
9632591
Gene. 1998 May 28;212(1):77-86
9661666
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13899-904
9811898
Infect Immun. 1999 Apr;67(4):2040-4
10085057
J Bacteriol. 1964 Sep;88:745-57
14208514
J Bacteriol. 2003 Apr;185(7):2080-95
12644477
Infect Immun. 2003 May;71(5):2404-13
12704110
EMBO J. 2003 Jun 16;22(12):2959-69
12805211
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8484-9
12815109
J Biol Chem. 2003 Aug 29;278(35):32794-800
12807879
Genetics. 1967 Mar;55(3):513-24
6068403
J Infect Dis. 1972 Jun;125(6):631-6
4624815
Proc Natl Acad Sci U S A. 1975 Jun;72(6):2284-8
166383
Infect Immun. 1980 May;28(2):546-56
6772562
Infect Immun. 1982 Aug;37(2):662-9
6811437
Rev Infect Dis. 1983 Nov-Dec;5 Suppl 5:S998-1004
6419322
Can J Microbiol. 1985 Apr;31(4):387-92
2988728
J Clin Microbiol. 1986 Aug;24(2):260-4
3018037
Nature. 2000 Aug 31;406(6799):959-64
10984043